Kornimate/medical-research-clean huggingface dataset:
supported employment: motivational enhancement for entry and outcome

Conditions: Psychotic Disorders; Bipolar Disorder; Unemployment

Summary: the purpose of this study is to compare 6 monthly counseling sessions to 6 monthly information sessions on veterans' decisions to (a) participate in vocational rehabilitation services and (b) become employed.

approximately 85-90% of those with serious mental illness are unemployed (9, 10). this level of unemployment exists despite the finding that, among people who have a psychiatric disability and are unemployed, 55-61% desire employment, with the total reaching 75% when concern about losing benefits was taken into account (1, 2). the rewards of employment for adults with smi are greater than simply an increase in financial resources. studies have found that people with serious mental illness who worked competitively scored higher on measures of self-esteem, satisfaction with finances, leisure, and overall life satisfaction compared to those worked little or not at all (11). supported employment (se) has been more effective than any other vocational rehabilitation approach for this population (3, 4) and the va has mandated that se be integrated into all current vha compensated work therapy (cwt) programs (vha directive 2007-005). two areas of concern include (a) national utilization of se services is low (13), and (b) the percentage of se participants who obtain at least one job during the studies averages 56% even though everyone who enters the program expressed an interest in working (13). motivational interviewing (mi) is an evidence-based practice that has been effective in enhancing a range of clinical services (6), but has just recently been applied to employment and vocational services by drebing et al. (7) and glynn et al (8). the proposed project is a randomized trial of adapted motivational interviewing for supported employment (ami-se) provided to veterans and their significant others (family members or key friends) in order to address the internal and external barriers to the veteran enrolling in supported employment and returning to work.

Eligibility criteria:
inclusion criteria: * eligible to receive va services * diagnosis of serious mental illness: schizophrenia, schizoaffective, psychosis nos, bipolar disorder, or depression with psychotic features * currently unemployed * not currently enrolled in supported employment services * expects to stay within 100 miles of bedford, ma for the next 18 months * has a significant other (friend or family member) who is also willing to participate (a criterion required only from march 2011 to march 2012 of the recruitment period) exclusion criteria: * currently in prison * not able to provide informed consent * not able to speak and understand english

Keywords: veterans vocational rehabilitation
instructed home-based physical exercise for patients with liver cirrhosis

Conditions: Liver Cirrhosis

Summary: the study will compare two forms of advice regarding physical activity for patients hospitalized with cirrhosis that are preparing for leaving the hospital. one arm consists of current standard of care: simple oral advice on exercise. one arm instead gives patients a structured but simple paper template on physical activity.


Eligibility criteria:
inclusion criteria: * liver cirrhosis diagnosed with previous clinical assessment and radiology (de-formed liver, noduli, varices, collaterals, splenomegaly \>12 cm) or with biopsy (fibrosis grade 4). icd-code k70.3, k74.6. * meld \< 25 * understanding the swedish language. * signed informed consent. exclusion criteria: * performance status ≥3. * severe pain which prevents the patient to perform the physical activities, as judged by the attending physician at time of discharge. * previously liver transplanted * unlikely to be compliant to follow-up (living in other parts of sweden), as judged by the attending physician at time of discharge.
the incidence and the risk factors of nephrocalcinosis in very preterm infants

Conditions: Nephrocalcinosis; Preterm Infant

Summary: the study aims to assess the incidence and the risk factors of nephrocalcinosis in very preterm infants using patient data collected during hospitalisation at the neonatology centre.

nephrocalcinosis in preterm infants develops as a result of imbalance between the factors promoting or inhibiting formation of kidney stones. it is caused by intensive treatment as well as functional and morphological kidney immaturity. there is a correlation between the prevalence of nephrocalcinosis and low gestational age. the study aims prospectively to assess the incidence and the risk factors of nephrocalcinosis in very preterm infants less than 32 weeks of gestation.

Eligibility criteria:
inclusion criteria: * preterm infants of the gestational age of \<32 weeks; * parental consent acquired. exclusion criteria: * death before 28 days of age; * congenital defects; * no kidney ultrasound results; * no parental consent.
first line dose-efficacy study of bactecal® d liquid for infant colic

Conditions: Colic

Summary: this randomized, open label, dose-response study will be realized at the first line with bactecal® d liquid. the objective is to investigate bactecal® d liquid in the context of infantile colics. the patients will be randomized into two arms, a and b, in function of the intervention dose. the quality of life of te parents as well as the daily median crying time and the number of daily crying will be assessed.


Eligibility criteria:
inclusion criteria: * full term healthy infant (37-41 weeks amenorrhea) * birth weight \>2750 g * aged between 2 and 8 weeks * presenting symptoms of infant colic as defined by rome iv criteria by zeevenhoven et al. 2017 * signed written informed consent of the parent/tutor exclusion criteria: * premature birth * using probiotics as a treatment, different from the one that could contain the formula at the time of study recruitment * acute or chronic illness as judged by the investigator which avoids the participation to the study . * parents unable to understand the requirements of study participation as judged by the investigator * malnutrition as judged by a body weight/height ratio \<5 %
first line metastatic colorectal cancer therapy in combination with folfox

Conditions: Colorectal Cancer

Summary: the purpose of this study is to see if cediranib in combination with folfox is effective in treating metastatic colorectal cancer and to see how it compares with avastin (bevacizumab) in combination with folfox.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of colon or rectal cancer * no prior systemic therapy for metastatic disease. any adjuvant/neoadjuvant oxaliplatin therapy must have been received \>12 months prior to study entry and adjuvant/neoadjuvant 5-fu must have been received \>6 months prior to study entry. exclusion criteria: * prior treatment with a vegf inhibitor, including bevacizumab and cediranib. * poorly controlled hypertension

Keywords: metastatic colorectal cancer recentin
electronic support for pulmonary embolism emergency disposition

Conditions: Pulmonary Embolism

Summary: to evaluate the impact of an integrated electronic clinical decision support system to facilitate risk stratification and site-of-care decision-making for patients with acute pulmonary embolism.

many low-risk emergency department patients with acute pulmonary embolism are routinely hospitalized despite being eligible for outpatient care. one impediment to home discharge is the difficulty of identifying which patients can safely forego hospitalization. this pragmatic clinical trial intends to evaluate the effect on emergency department disposition of a multicomponent intervention, including electronic clinical decision support system access, physician education, and physician-specific audit and feedback. the hypothesis for this study is that intervention sites, when compared with concurrent control sites, will see an increase in home discharges without an increase in 5-day pulmonary embolism-related return visits or 30-day all-cause mortality.

Eligibility criteria:
inclusion criteria: * acute objectively-confirmed pulmonary embolism, diagnosed in the emergency department exclusion criteria: * comfort-care only * left the ed against medical advice * current pe radiologically diagnosed \>12 hrs prior to arrival * recent dvt or pe diagnosed within 30 days * pregnant
evaluation of an ascensia diabetes care onyx plus investigational blood glucose monitoring system

Conditions: Diabetes

Summary: the purpose of this study was to determine if untrained subjects with diabetes can operate the investigational onyx plus blood glucose monitoring system (bgms) and obtain valid glucose results.


Eligibility criteria:
inclusion criteria: * males and females, 18 years of age and older * able to speak, read, and understand english * willing to complete all study procedures exclusion criteria: * hemophilia or other bleeding disorder * pregnancy * physical, visual, or neurological impairments that would make the person unable to perform testing with the bgm * previously participated in a bg monitor study using the onyx plus bgms * working for a medical laboratory, hospital, or other clinical setting that involves training on or clinical use of blood glucose monitors * working for a competitive medical device company, or having an immediate family member who works for such a company * a condition which, in the opinion of the investigator or designee, would put the person or study conduct at risk the enrollment goal for the intended use population: 1. at least 70% of subjects will be younger than age 65 2. at least 20% of subjects will have type 1 diabetes
phase ii study of vcr-cvad with rituximab consolidation and maintenance for untreated mantle cell lymphoma

Conditions: Mantle Cell Lymphoma

Summary: patients will receive rituximab, bortezomib, cyclophosphamide, doxorubicin, vincristine, dexamethasone in three week intervals for 6 cycles; then rituximab consolidation (weekly x 4) , then one dose of rituximab every 12 weeks until 5 years or disease progression.

primary objective is to estimate the overall response rate (orr) and the complete response rate (crr) to the vcr cvad regimen (response rate at completion of induction). patients will receive rituximab, bortezomib, cyclophosphamide, doxorubicin, vincristine, dexamethasone in three week intervals for 6 cycles; then rituximab consolidation (weekly x 4) , then one dose of rituximab every 12 weeks until 5 years or disease progression.

Eligibility criteria:
inclusion criteria: * histologically confirmed cd20+ mantle cell lymphoma, with measurable or evaluable disease, no prior chemotherapy, immunotherapy or radiotherapy except for 1 cycle of chop-like chemotherapy. exclusion criteria: * patients with known cns disease, known hiv infection, grade 2 or greater peripheral neuropathy, history of myocardial infarction in last 6 months, or patients who are hepatitis b surface antigen positive.

Keywords: untreated mantle cell lymphoma
treatment outcomes of vaginal prolapse repair

Conditions: Vaginal Prolapse

Summary: chart review conducted on all patients having had prolift surgery since 2005 by dr. lary sirls, dr. predeep nagaraju and dr. kenneth peters at william beaumont hospital.

chart review conducted on all patients having had prolift surgery since 2005 by dr. lary sirls, dr. predeep nagaraju and dr. kenneth peters at william beaumont hospital. preoperative, intraoperative and post-operative data will be collected from the hospital and physician medical records. a questionnaire will be mailed to patients whose charts have been reviewed to assess urinary and bowel function, satisfaction with treatment and changes in sexual function. completion of the questionnaire is voluntary.

Eligibility criteria:
inclusion criteria: * women having prolift repair at william beaumont hospital exclusion criteria: * none

Keywords: vaginal prolapse
effects of acute pain on cognitive performance in young adults

Conditions: Pain, Acute; Cognition

Summary: the effects of pain on cognitive performance have not been thoroughly investigated. broadly, the purpose of this research is to investigate the effects of acute pain on performance of a variety of cognitive performance measures. the investigators hypothesize that acute pain impairs cognitive performance, particularly cognitive measures of working memory, attention, and processing speed.


Eligibility criteria:
abbreviations: hr= heart rate, bpm= beats per minute; bp= blood pressure; add= attention deficit disorder; adhd= attention deficit hyperactivity disorder; moca= montreal cognitive assessment; gad-7= generalized anxiety disorder 7 scale; phq-2, phq-9= patient health questionnaire-2 and -9. inclusion criteria: 1. 18-35 years old 2. self-identifying as generally medically healthy 3. able to read, write and speak english 4. able to provide informed consent 5. willing to undergo the experimental pain or non-painful electrical stimulation, if selected exclusion criteria: 1. resting hr \ 100 bpm 2. resting bp \ 140/95 mmhg 3. any history or current mental health condition, learning/developmental disability or cognitive impairment, including add/adhd, severe anxiety, severe depression, autism spectrum disorder, insomnia, mild cognitive impairment, etc. 4. score on the moca \<23 5. score on the gad-7 ≥ 10 6. score on the phq-2 ≥ 2 and score on the phq-9 ≥ 10 7. any current (within last 3 month) or chronic medical conditions, including any musculoskeletal, cardiovascular, endocrine, pulmonary, metabolic, psychiatric or neurological diagnosis 8. any implanted electronic medical devices (i.e., cardiac pacemakers, cardiac defibrillators, spinal cord neurostimulators) 9. any impaired sensation or weakness in either lower extremity or in the area targeted for the stimulus 10. history of serious concussion or head injury, defined as a loss of consciousness for \> 5 minutes and/or requiring medical treatment, or \> 2 concussions over the lifespan 11. any history of acute or chronic problems with balance, any dizziness, or \> 1 fall in the last 12 months 12. taking 4 or more medications 13. currently or regularly using any analgesic medications, over-the-counter remedies, or any other treatment for the purposes of pain relief (i.e., baby aspirin for heart health permitted, etc.) 14. any current or chronic pain condition during the last year, located anywhere in the body 15. allergy to capsaicin or hot peppers 16. any skin lesion, breakage or irritation in the area targeted for the painful stimulus 17. skin sensitivity to soaps/creams/perfumes or to heat 18. poor circulation in the area targeted for the painful stimulus 19. prior participation in a locomotor learning study in this lab within the last 2 years

Keywords: acute pain cognition pain cognitive ability young adults
evaluation of efficacy of lycium barbarum polysaccharide in patients with major depressive disorder

Conditions: Major Depressive Disorder; Depression; Depressive Disorder

Summary: lycium barbarum, a traditional chinese herbal medicine, is a commonly used herb in the traditional chinese pharmacopoeia. its main active ingredient, lycium barbarum polysaccharide (lbp), is reported to have neuroprotective effects. animal studies suggested that lbp has neuroprotective effect on optic ganglion cells. in animal models of depression, lbp can improve depressive symptom by improving synaptic plasticity. however, its clinical effect remains to be studied. we will conduct a 6-week double-blind, randomized, placebo-con-trolled trial in patients with major depressive disorder (mdd). the purpose of this clinical trial is to investigate the efficacy of lbp in patients with mdd.


Eligibility criteria:
inclusion criteria: 1. age: 18-60 years old 2. sex: both men and women 3. compliance with the diagnostic and statistical manual of mental disorders-5 (dsm-5) diagnostic criteria for major depressive disorder 4. hamilton depression scale scored more than 18 points. 5. no contraindication of taking lycium barbarum polysaccharide exclusion criteria: 1. comorbidity with other mental disorders 2. severe somatic diseases 3. current use of traditional chinese medicine 4. suicide concept, attempt, act and attempted suicide 5. psychiatric symptoms 6. taking hormones and endocrine drugs 7. long-term use of wolfberry in recent three months

Keywords: major depressive disorder lycium barbarum polysaccharide
efficacy and safety of adalimumab in subjects with moderate to severe chronic plaque psoriasis

Conditions: Psoriasis

Summary: the two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were then withdrawn from adalimumab treatment.

study m03-658 was a continuation study for participants with moderate to severe psoriasis who had participated in a prior psoriasis adalimumab study. study m03-658 consisted of three sequential treatment periods. the first period was period o, in which participants received open-label treatment with adalimumab (40 mg every other week or 40 mg every week) for a minimum of 104 weeks and a maximum of 252 weeks. period o was the only period of the study until may 2008, when the subsequent periods were added via amendment to the protocol. at that time, participants who had achieved satisfactory therapeutic response (a physician's global assessment \[pga\] of 0, 1, or 2 \[clear, minimal, or mild\]) were given the opportunity to discontinue from the study or to continue and participate in the subsequent two periods. the second period was period w, a maximum of 52 weeks, in which participants with a pga of 2 (mild) or less were withdrawn from adalimumab treatment (i.e., participants received no treatment) until relapse of their psoriasis occurred (defined as a pga of 3 \[moderate\] or worse). the third period was period r, a 16-week period in which participants were retreated with open-label adalimumab (80 mg initial dose followed by 40 mg every other week). period o was designed to evaluate the first objective regarding long-term efficacy and safety of adalimumab treatment, and period r was designed to evaluate the effectiveness of adalimumab retreatment following relapse. specific subsets of the study population that were identified as the populations of interest were the modified intent-to-treat populations for period w and period r, and these are described further in the outcome measures.

Eligibility criteria:
inclusion criteria: * subject was age 18 or older and in good health (investigator discretion) with a recent stable medical history. * subjects who met the requirements from previous adalimumab psoriasis study participation. exclusion criteria: * subject considered by the investigator, for any reason, to be an unsuitable candidate for the study. * female subject who was pregnant or breast-feeding or considering becoming pregnant.
adapted physical activity in patients with lower limb peripheral arterial disease

Conditions: Peripheral Arterial Disease

Summary: the prevalence of peripheral arterial disease is 12.2% in france. intermittent claudication is the most common symtom of this disease. during physical exercise, such as walking, blood oxygen (o2) requirements increase. the development of atherosclerosis in the lower limbs, causes narrowing of the arteries and limits the increase in blood flow required for muscular effort. patients then experience muscle pain, the intensity of which gradually increases until it forces them to stop. after stopping, the pain subsides and disappears in less than 10 minutes. the location of the pain (calves and/or thighs and/or buttocks) is related to the location of the ischemia (distal in the calf, proximal in the thigh or buttock, or proximo-distal if several locations). this can have different consequences on the biomechanical parameters of walking and muscle activity. to date, the impact of this localization on physical capacity has never been studied. these limitations are very disabling and impact the quality of life of patients. in addition, poor lower limb performance is associated with higher mortality. reducing symptomatology and improving functional abilities is therefore a major issue in patients with peripheral arterial disease. this can be achieved through the practice of an adapted physical activity, an essential recommendation in the care of patients with peripheral arterial disease. our main hypothesis is that the physical activity rehabilitation protocol "activ'ao" will improve the functional capacities of patients with peripheral arterial disease who have followed the program with the localization of ischemia with a greater consideration than in patients in the group following a "standard" apa protocol. improvements in functional abilities (such as walking) will lead to improvements in quality of life.


Eligibility criteria:
inclusion criteria: * patient with lower limb peripheral arterial disease with ipsc \< 0.90, arterial stenosis in the lower limbs and intermittent claudication * no contraindication to physical activity exclusion criteria: * severe or unstable cardiopulmonary pathologies, contraindicating exercise training * unstable angina or myocardial infarction \<3 months * severe rheumatological pathology of the lower limbs * amputee of a lower or upper limb fitted with a device * extensive dermatosis of the lower limbs * known nyha grade iii or iv heart failure * known severe respiratory pathology * parkinson's disease, hemiplegia or paraplegia

Keywords: peripheral arterial disease, adapted physical activity
oxygen level and safe emergence from anesthesia

Conditions: Focus of Study is Postoperative Pulmonary Atelectacis

Summary: using a protective ventilation strategy during general anesthesia from pre-oxygenation to emergence and selecting patients without risk of a difficult airway or intubation, a lower fraction of inspiratory oxygen (fio2) can be used during extubation. this might reduce the postoperative area of atelectasis without desaturations becoming more common.


Eligibility criteria:
inclusion criteria: * no sign of difficult airway or intubation * day case surgery in total intravenous anesthesia with laryngeal mask airway without adding regional anesthesia of plexus brachialis or muscle relaxant. * body mass index less than 35. * american society of anesthesiologists physical status (asa) class i-iii exclusion criteria: * body mass index 35 or higher * increased risk of aspiration * obstructive sleep apnea syndrome * procedures during surgery making a former easy airway a difficult airway * need for opioids after extubation * hypothermia
anti-mullerian hormone (amh) after treatment of endometriomas with alcohol sclerotherapy versus surgery: clinical trial

Conditions: Endometrioma; Fertility Disorders

Summary: the purpose of this multicenter study is to compare the ovarian reserve after alcohol sclerosis of the endometriomas against conventional surgery (amh, follicle stimulating hormone (fsh) and antral follicles count) as well as the complications and costs between the 2 procedures.

clinical trial phase iii, multicenter, national, open, parallel-group assignment 1: 1, stratified by age, previous oophorectomy and uni- or bilateral ovarian involvement. patients with suspected ovarian endometrioma by ultrasound will be randomized into 2 groups: (a) study group: echoguided aspiration plus sclerosis with alcohol; (b) control group: laparoscopic cystectomy. pre-treatment, and 6 months after treatment, amh values will be determined. complications, recurrences and costs from each treatment will be collected.

Eligibility criteria:
inclusion criteria: * uni- or bilocular endometrioma according ultrasounds * endometrioma size: 30-100 mm when symptoms were present and 50-100 mm if asymptomatics * \> 3 months from diagnosis * ca125 \<200 iu/ml and human epididymis protein 4 (he4) \< 70, exclusion criteria: * previous gynecological cancer * symptomatic severe extraovarian endometriosis * dermoid or high risk of malignancy cysts * pregnancy * mental disability